Regression of left ventricular hypertrophy in hemodialyzed patients is possible: a follow-up study

Şerban Ardeleanu1, Larisa Panaghiu, Octavian Prisadă

  • 1Dialysis and Transplantation Center, Dr CI Parhon University Hospital, Blvd Carol 1st No 50, 700503 Iaşi, Romania. serbard@yahoo.com

Insights

Regression of left ventricular hypertrophy (LVH) is achievable in hemodialyzed patients. Serial echocardiography showed significant LVH regression and improved cardiac structure over a 10-year period, highlighting a key objective for dialysis centers.

Area of Science:

  • Cardiology
  • Nephrology
  • Medical Imaging

Background:

  • Limited research exists on serial changes in left ventricular mass (LVM) and associated risk factors.
  • Echocardiographic assessment of left ventricular (LV) structure and function trends over a decade in hemodialysis patients was investigated.

Purpose of the Study:

  • To describe trends in LV structure and function using echocardiography over 10 years.
  • To compare current findings with previous data from a smaller patient cohort.
  • To identify factors influencing changes in LV mass index (LVMi) in hemodialysis patients.

Main Methods:

  • A cohort of 334 hemodialyzed patients was followed from January 1999 to March 2009.
  • Serial echocardiography was performed throughout the study period.
  • Mean biochemical parameters (hemoglobin, serum proteins, calcium, phosphate) were analyzed alongside echocardiographic data.

Main Results:

  • A 70.5% survival rate was observed at the study's end.
  • Significant regression of left ventricular hypertrophy (LVH) was noted, with LVMi decreasing by 15.4% in patients with complete data.
  • Relative wall thickness also showed significant regression (0.46 to 0.42).
  • Changes in LVMi correlated significantly with hemoglobin level fluctuations.

Conclusions:

  • Regression of LVH is attainable in hemodialysis patients.
  • Achieving LVH regression is a critical goal for dialysis centers.
  • Serial echocardiography is valuable for monitoring cardiac remodeling in this population.
Abstract

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Mitral Regurgitation IV: Nursing Management01:28

Mitral Regurgitation IV: Nursing Management

Mitral regurgitation (MR) is a condition where the mitral valve does not close properly, leading to the backward flow of blood from the left ventricle into the left atrium during systole. This condition can arise from various causes, including rheumatic fever, infective endocarditis, or degenerative valve disease. Effective nursing management is crucial to optimizing patient outcomes and involves comprehensive assessment and targeted interventions.Comprehensive Patient AssessmentA detailed...
Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...